Abvc Biopharma (ABVC) Long-Term Deferred Tax (2014 - 2025)

Abvc Biopharma (ABVC) has reported Long-Term Deferred Tax for 10 consecutive years, with $6.0 million the latest figure, recorded in Q3 2025.

• For the quarter ending Q3 2025, Long-Term Deferred Tax changed N/A year-over-year to $6.0 million; the trailing twelve-month figure through Sep 2025 stood at $6.0 million (changed N/A YoY), and the FY2024 full-year result was $5.7 million, down 9.62% from the prior year.
• Long-Term Deferred Tax retreated to $6.0 million in Q3 2025 per ABVC's latest filing, from $6.0 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $6.6 million in Q4 2022 and bottomed at $34256.0 in Q3 2023.
• Historically, Long-Term Deferred Tax has averaged $3.1 million across 5 years, with a median of $1.9 million in 2021.
• The sharpest annual moves came in 2023 and 2024: Long-Term Deferred Tax tumbled 96.72% in 2023, then soared 17498.35% in 2024.
• Over 5 years, Long-Term Deferred Tax stood at $981912.0 in 2021, then soared by 569.77% to $6.6 million in 2022, then slipped by 4.49% to $6.3 million in 2023, then dropped by 9.62% to $5.7 million in 2024, then advanced by 5.61% to $6.0 million in 2025.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $6.0 million, $6.0 million, and $5.7 million for Q3 2025, Q2 2025, and Q4 2024 respectively.